Volume 63, Issue 2, Pages (February 2003)

Slides:



Advertisements
Similar presentations
Volume 65, Issue 1, Pages (January 2004)
Advertisements

Volume 63, Issue 6, Pages (June 2003)
Volume 72, Issue 11, Pages (December 2007)
Volume 76, Issue 1, Pages (July 2009)
Volume 54, Issue 1, Pages (July 1998)
Volume 57, Issue 1, Pages (January 2000)
Volume 54, Issue 3, Pages (September 1998)
Volume 72, Issue 11, Pages (December 2007)
Volume 64, Issue 1, Pages (July 2003)
Volume 61, Issue 2, (February 2002)
IN-1130, a novel transforming growth factor-β type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy  J.-A. Moon,
Volume 83, Issue 5, Pages (May 2013)
Volume 65, Issue 1, Pages (January 2004)
Volume 60, Issue 2, Pages (August 2001)
Volume 64, Issue 2, Pages (August 2003)
Volume 68, Issue 5, Pages (November 2005)
Volume 66, Issue 6, Pages (December 2004)
Volume 61, Issue 3, Pages (March 2002)
Volume 58, Issue 6, Pages (December 2000)
Volume 75, Issue 10, Pages (May 2009)
Volume 62, Issue 1, Pages (July 2002)
Mast cells decrease renal fibrosis in unilateral ureteral obstruction
Volume 60, Issue 3, Pages (September 2001)
Volume 63, Issue 6, Pages (June 2003)
Volume 65, Issue 6, Pages (June 2004)
Paricalcitol attenuates cyclosporine-induced kidney injury in rats
Volume 69, Issue 1, Pages (January 2006)
Volume 63, Issue 2, Pages (February 2003)
Volume 59, Issue 5, Pages (May 2001)
Hiroyuki Yanagisawa, Nobuyuki Yamazaki, Gen Sato, Osamu Wada 
The renal lesions that develop in neonatal mice during angiotensin inhibition mimic obstructive nephropathy  Yoichi Miyazaki, Shinya Tsuchida, Agnes Fogo,
Volume 63, Issue 5, Pages (May 2003)
Volume 57, Issue 5, Pages (May 2000)
Isotretinoin alleviates renal damage in rat chronic glomerulonephritis
Volume 64, Issue 4, Pages (October 2003)
Volume 67, Issue 5, Pages (May 2005)
Volume 62, Issue 2, Pages (August 2002)
Volume 55, Issue 2, Pages (February 1999)
Volume 57, Issue 3, Pages (March 2000)
Volume 79, Issue 4, Pages (February 2011)
Volume 61, Issue 1, Pages (January 2002)
Volume 59, Issue 3, Pages (March 2001)
Volume 66, Issue 5, Pages (November 2004)
Volume 68, Issue 6, Pages (December 2005)
Volume 72, Issue 12, Pages (December 2007)
Volume 63, Issue 1, Pages (January 2003)
Volume 67, Issue 2, Pages (February 2005)
C5b-9 regulates peritubular myofibroblast accumulation in experimental focal segmental glomerulosclerosis  Gopala K. Rangan, Jeffrey W. Pippin, William.
Volume 67, Issue 4, Pages (April 2005)
Volume 71, Issue 9, Pages (May 2007)
Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis  H.-C. Yang, L.-J. Ma, J. Ma, A.B. Fogo 
Volume 56, Issue 5, Pages (November 1999)
Volume 59, Issue 5, Pages (May 2001)
Volume 61, Issue 1, Pages (January 2002)
Volume 55, Issue 3, Pages (March 1999)
Volume 65, Issue 6, Pages (June 2004)
Volume 58, Issue 3, Pages (September 2000)
TGF-β type II receptor deficiency prevents renal injury via decrease in ERK activity in crescentic glomerulonephritis  C.Y. Song, B.C. Kim, H.K. Hong,
Volume 60, Issue 5, Pages (November 2001)
Volume 58, Issue 5, Pages (November 2000)
Volume 58, Issue 4, Pages (October 2000)
Volume 59, Issue 5, Pages (May 2001)
Volume 56, Issue 6, Pages (December 1999)
Jens Gaedeke, Nancy A. Noble, Wayne A. Border  Kidney International 
The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury?  Richard E. Gilbert, Mark E. Cooper  Kidney.
Volume 59, Issue 2, Pages (February 2001)
Volume 65, Issue 1, Pages (January 2004)
Volume 70, Issue 1, Pages (July 2006)
Tubulointerstitial changes and arteriolar hyalinosis in diabetic kidney disease. Tubulointerstitial changes and arteriolar hyalinosis in diabetic kidney.
Volume 75, Issue 2, Pages (January 2009)
Presentation transcript:

Volume 63, Issue 2, Pages 454-463 (February 2003) Long-term treatment with ramipril attenuates renal osteopontin expression in diabetic rats  Can Li, Chul Woo Yang, Cheol Whee Park, Hee Jong Ahn, Wan Young Kim, Kun Ho Yoon, Sun Hee Suh, Sun Woo Lim, Jung Ho Cha, Yong Soo Kim, Jin Kim, Yoon Sik Chang, Byung Kee Bang  Kidney International  Volume 63, Issue 2, Pages 454-463 (February 2003) DOI: 10.1046/j.1523-1755.2003.00751.x Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 1 Body weight (A), systolic blood pressure (B), creatinine clearance (CCr) rate (C), and urinary protein excretion (D) in OLETF and LETO rats treated with ramipril or vehicle. Data were obtained from 10 animals per group. Comparisons at different time points were made using repeated measures ANOVA. Symbols are: (•) LETO control; (○) LETO ramipril; (▾) OLETF control; (▿) OLETF ramipril; #P < 0.05 vs. LETO controls; ##P < 0.01 vs. OLETF controls; *P < 0.05 vs. OLETF-ramipril rats (start of study); **P < 0.05 vs. OLETF controls (start of study). Kidney International 2003 63, 454-463DOI: (10.1046/j.1523-1755.2003.00751.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 2 Plasma glucose concentrations during oral glucose tolerance test (OGTT) in OLETF and LETO rats treated with ramipril or vehicle at initiation (A), three months (B), and nine months (C). Symbols are: (•) LETO control; (○) LETO ramipril; (▾) OLETF control; (▿) OLETF ramipril; #P < 0.05 vs. LETO rats. Kidney International 2003 63, 454-463DOI: (10.1046/j.1523-1755.2003.00751.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 3 Photomicrographs of PAS staining and semiquantitative analysis of glomerulosclerosis in each group. (A) Normal glomerulus. (B) Arteriolar hyalinosis. (C) Widening of glomerular basement membranes. (D) Nodular lesions or glomerulosclerosis. #P < 0.001 vs. LETO controls; ##P = 0.004 vs. OLETF controls. Original magnification ×400. Kidney International 2003 63, 454-463DOI: (10.1046/j.1523-1755.2003.00751.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 4 Extent of tubulointerstitial fibrosis in LETO and OLETF rats treated with ramipril or vehicle during nine months. (A) LETO controls. (B) LETO-ramipril treated rats. (C) OLETF controls. (D) OLETF-ramipril treated rats. OLETF controls showed renal tubular atrophy, inflammatory cell infiltration, and extracellular matrix deposition, whereas blockade of angiotensin II with ramipril significantly attenuated these structural changes. #P < 0.001 vs. LETO controls; ##P = 0.002 vs. OLETF controls. Masson trichrome staining, original magnification ×100. Kidney International 2003 63, 454-463DOI: (10.1046/j.1523-1755.2003.00751.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 5 Northern blot and quantitative analyses of osteopontin (A) and transforming growth factor-β1 mRNAs (B). Northern blots showing that OPN and TGF-β1 mRNAs were markedly up-regulated in OLETF controls, whereas treatment with ramipril for nine months abrogated this action. OPN and TGF-β1 mRNAs were normalized for GAPDH mRNA (OPN, TGF-β1/GAPDH ratio, %). #P < 0.001 vs. LETO controls; ##P < 0.005 vs. OLETF controls. Kidney International 2003 63, 454-463DOI: (10.1046/j.1523-1755.2003.00751.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 6 Photomicrographs of immunohistochemistry (A1-D1) and in situ hybridization (A2-D2) of osteopontin in kidney cortex of LETO and OLETF rats treated with ramipril or vehicle for nine months. Both mRNA and protein of OPN were absent in cortical tubular epithelium of LETO rats (A and B). In the OLETF controls, however, their expression was markedly increased (C). With ramipril treatment, these increased OPN mRNA and protein expressions were abrogated (D). Original magnification ×100. Kidney International 2003 63, 454-463DOI: (10.1046/j.1523-1755.2003.00751.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 7 Photomicrographs of immunohistochemistry of TGF-β1 in kidney cortex of LETO and OLETF rats treated with ramipril or vehicle for nine months. (A) LETO controls. (B) LETO–ramipril treated rats. (C) OLETF controls. (D) OLETF-ramipril treated rats. TGF-β1 protein was almost negative in cortical tubules and interstitium of LETO rats, whereas its immunoreactivity was significantly increased in OLETF controls. With ramipril treatment, the increased TGF-β1 expression was decreased. Original magnification ×100. Kidney International 2003 63, 454-463DOI: (10.1046/j.1523-1755.2003.00751.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 8 Immunohistochemical staining of macrophages and semiquantitative counts of ED-1 positive cells within the tubular interstitium in each group. (A) LETO controls. (B) LETO–ramipril treated rats. (C) OLETF controls. (D) OLETF-ramipril treated rats. OLETF controls revealed focal ED-1 positive cell accumulation within the tubular interstitium compared with LETO rats, especially in injured areas. Ramipril significantly decreased the number of ED-1 positive cells. Original magnification ×100. #P < 0.001 vs. LETO controls; ##P < 0.001 vs. OLETF controls. Kidney International 2003 63, 454-463DOI: (10.1046/j.1523-1755.2003.00751.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 9 Relationship between osteopontin mRNA expression and macrophage accumulation and tubulointerstitial injury. The expression of OPN mRNA correlated well with the number of ED-1 positive cells (A) and the tubulointerstitial fibrosis score (B) in the OLETF rats. Data are from 20 animals with diabetes analyzed using Pearson single correlation coefficient. In A, r = 0.560 and P < 0.01; in B, r = 0.500 and P < 0.05. Kidney International 2003 63, 454-463DOI: (10.1046/j.1523-1755.2003.00751.x) Copyright © 2003 International Society of Nephrology Terms and Conditions